INR 79.0
(1.69%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 162.22 Million INR | -35.62% |
2022 | 1.05 Billion INR | 4.28% |
2021 | 1 Billion INR | 26.06% |
2020 | 798.87 Million INR | 17.05% |
2019 | 682.52 Million INR | 3.29% |
2018 | 660.77 Million INR | -5.63% |
2017 | 700.22 Million INR | 92.51% |
2016 | 363.73 Million INR | 10.02% |
2015 | 330.6 Million INR | 34.7% |
2014 | 245.43 Million INR | 19.72% |
2013 | 205.01 Million INR | 5.31% |
2012 | 194.67 Million INR | 1.89% |
2011 | 191.07 Million INR | 125.32% |
2010 | 84.8 Million INR | 22.92% |
2009 | 68.98 Million INR | 13.01% |
2008 | 61.04 Million INR | 15.44% |
2007 | 52.88 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 183.67 Million INR | 52.93% |
2023 Q2 | 322.11 Million INR | 14.94% |
2023 Q1 | 280.24 Million INR | 9.39% |
2023 FY | 676.14 Million INR | -35.62% |
2023 Q4 | 207.75 Million INR | -14.96% |
2023 Q3 | 244.31 Million INR | -24.15% |
2022 Q3 | 263.74 Million INR | -2.46% |
2022 Q4 | 256.19 Million INR | -2.86% |
2022 FY | 1.05 Billion INR | 4.28% |
2022 Q1 | 259.88 Million INR | -38.0% |
2022 Q2 | 270.38 Million INR | 4.04% |
2021 Q3 | 152.29 Million INR | -32.82% |
2021 Q2 | 226.69 Million INR | 5.25% |
2021 Q1 | 215.37 Million INR | 19.57% |
2021 Q4 | 419.18 Million INR | 175.25% |
2021 FY | 1 Billion INR | 26.06% |
2020 Q2 | 207.29 Million INR | 8.79% |
2020 FY | 798.87 Million INR | 17.05% |
2020 Q1 | 190.54 Million INR | 18.23% |
2020 Q4 | 180.12 Million INR | -18.46% |
2020 Q3 | 220.9 Million INR | 6.56% |
2019 Q4 | 161.16 Million INR | -7.98% |
2019 FY | 682.52 Million INR | 3.29% |
2019 Q1 | 174.36 Million INR | 109.24% |
2019 Q2 | 171.84 Million INR | -1.44% |
2019 Q3 | 175.14 Million INR | 1.92% |
2018 Q1 | 179.69 Million INR | -8.45% |
2018 FY | 660.77 Million INR | -5.63% |
2018 Q4 | 83.33 Million INR | -57.78% |
2018 Q3 | 197.38 Million INR | -1.48% |
2018 Q2 | 200.35 Million INR | 11.5% |
2017 Q2 | 182.69 Million INR | -12.27% |
2017 FY | 700.22 Million INR | 92.51% |
2017 Q4 | 196.28 Million INR | 20.63% |
2017 Q1 | 208.24 Million INR | 23.33% |
2017 Q3 | 162.71 Million INR | -10.93% |
2016 Q2 | 141.23 Million INR | 6.12% |
2016 FY | 363.73 Million INR | 10.02% |
2016 Q4 | 168.85 Million INR | -6.23% |
2016 Q3 | 180.07 Million INR | 27.5% |
2016 Q1 | 133.09 Million INR | 243.02% |
2015 FY | 330.6 Million INR | 34.7% |
2015 Q1 | 121.99 Million INR | 361.87% |
2015 Q2 | 170.79 Million INR | 40.0% |
2015 Q3 | 130.87 Million INR | -23.37% |
2015 Q4 | -93.06 Million INR | -171.11% |
2014 Q3 | 108.27 Million INR | 27.95% |
2014 Q4 | -46.58 Million INR | -143.03% |
2014 Q2 | 84.62 Million INR | -14.63% |
2014 Q1 | 99.11 Million INR | 218.26% |
2014 FY | 245.43 Million INR | 19.72% |
2013 Q1 | 79.36 Million INR | 286.48% |
2013 FY | 205.01 Million INR | 5.31% |
2013 Q4 | -83.81 Million INR | -175.71% |
2013 Q3 | 110.7 Million INR | 12.13% |
2013 Q2 | 98.73 Million INR | 24.41% |
2012 Q3 | 89.84 Million INR | 18.21% |
2012 Q2 | 76.01 Million INR | 6.49% |
2012 Q1 | 71.37 Million INR | 175.73% |
2012 FY | 194.67 Million INR | 1.89% |
2012 Q4 | -42.55 Million INR | -147.37% |
2011 FY | 191.07 Million INR | 125.32% |
2011 Q3 | 88.09 Million INR | 0.0% |
2011 Q4 | -94.25 Million INR | -207.0% |
2010 FY | 84.8 Million INR | 22.92% |
2009 FY | 68.98 Million INR | 13.01% |
2008 FY | 61.04 Million INR | 15.44% |
2007 FY | 52.88 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Hester Biosciences Limited | 908.84 Million INR | 82.15% |
RPG Life Sciences Limited | 1.63 Billion INR | 90.081% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 88.435% |
Ipca Laboratories Limited | 18.98 Billion INR | 99.146% |
Aarti Drugs Limited | 1.16 Billion INR | 86.104% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 94.723% |
Albert David Limited | 1.02 Billion INR | 84.191% |
Alembic Limited | 872.45 Million INR | 81.406% |
Alkem Laboratories Limited | 32.83 Billion INR | 99.506% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 98.978% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | 64.391% |
Bajaj HealthCare Limited | 985.34 Million INR | 83.536% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -2278.71% |
Brooks Laboratories Limited | 51.18 Million INR | -216.975% |
Eris Lifesciences Limited | 4.94 Billion INR | 96.718% |
FDC Limited | 3.49 Billion INR | 95.365% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 98.606% |
Gufic Biosciences Limited | 1.18 Billion INR | 86.328% |
Hikal Limited | 4.46 Billion INR | 96.366% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 92.363% |
Ind-Swift Limited | 946.56 Million INR | 82.861% |
Innova Captab Limited | 931.03 Million INR | 82.575% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 92.629% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | 63.008% |
Jubilant Pharmova Limited | 14.45 Billion INR | 98.878% |
Kilitch Drugs (India) Limited | 412.42 Million INR | 60.665% |
Laurus Labs Limited | 11.9 Billion INR | 98.638% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 84.898% |
Lupin Limited | 125.09 Billion INR | 99.87% |
Medico Remedies Limited | 59.67 Million INR | -171.853% |
Morepen Laboratories Limited | 1.98 Billion INR | 91.837% |
Nectar Lifesciences Limited | 932.7 Million INR | 82.607% |
Orchid Pharma Limited | 800.77 Million INR | 79.741% |
Procter & Gamble Health Limited | 2.99 Billion INR | 94.584% |
Sigachi Industries Limited | 579.88 Million INR | 72.024% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 93.648% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.895% |
Themis Medicare Limited | 1.12 Billion INR | 85.59% |
Unichem Laboratories Limited | 6.72 Billion INR | 97.588% |
Vaishali Pharma Limited | 84.02 Million INR | -93.062% |
Venus Remedies Limited | 1.91 Billion INR | 91.534% |
Wanbury Limited | 978.96 Million INR | 83.429% |
Windlas Biotech Limited | 1 Billion INR | 83.882% |
ZIM Laboratories Limited | 1.01 Billion INR | 83.986% |
Sakar Healthcare Limited | 204.07 Million INR | 20.507% |
Aurobindo Pharma Limited | 55.65 Billion INR | 99.709% |
Divi's Laboratories Limited | 14.17 Billion INR | 98.855% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 93.441% |
Mankind Pharma Limited | 29.27 Billion INR | 99.446% |
Sequent Scientific Limited | 2.9 Billion INR | 94.409% |
Neuland Laboratories Limited | 2.92 Billion INR | 94.463% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 98.903% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.654% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.87% |
Amrutanjan Health Care Limited | 2.09 Billion INR | 92.253% |
Wockhardt Limited | 8.48 Billion INR | 98.087% |
Bal Pharma Limited | 555.62 Million INR | 70.803% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.831% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 88.569% |
Par Drugs and Chemicals Limited | 58.28 Million INR | -178.321% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 92.54% |
Shilpa Medicare Limited | 3.33 Billion INR | 95.134% |
Valiant Laboratories Limited | 138.02 Million INR | -17.532% |
Ajanta Pharma Limited | 30.46 Billion INR | 99.467% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -1041.406% |
Granules India Limited | 10.31 Billion INR | 98.427% |
Medicamen Biotech Limited | 335.16 Million INR | 51.598% |
Syncom Formulations (India) Limited | 345.63 Million INR | 53.064% |
Piramal Enterprises Limited | 63.65 Billion INR | 99.745% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.243% |
NATCO Pharma Limited | 10.05 Billion INR | 98.387% |
Suven Life Sciences Limited | 109.75 Million INR | -47.816% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -251.478% |
Strides Pharma Science Limited | 9.16 Billion INR | 98.229% |
Indoco Remedies Limited | 12.06 Billion INR | 98.655% |
Alpa Laboratories Limited | 127.38 Million INR | -27.358% |
Lasa Supergenerics Limited | 291.17 Million INR | 44.285% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 94.727% |